search
Back to results

Effect of Surgical Revascularization on Hemorrhagic Moyamoya Disease (ESRHMMD)

Primary Purpose

Moyamoya Disease

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Conservative treatment
Sponsored by
Affiliated Hospital to Academy of Military Medical Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Moyamoya Disease focused on measuring revascularization, hemorrhagic moyamoya disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • DSA/MRA shows stenosis or occlusion in the distal internal carotid artery or the proximal portion of anterior/middle cerebral artery
  • Abnormal vascular network appeared in the brain
  • Lesions showed bilateral changes
  • Age≥18 years
  • With the onset of cerebral hemorrhage
  • No cerebral infarction or cerebral hemorrhage occurred within the last month
  • At least one month after the acute phase of cerebral hemorrhage or related diseases was treated

Exclusion Criteria:

  • Patients with moyamoya syndrome secondary to systemic diseases such as arteriosclerosis, sickle cell anemia, radiation therapy, etc..
  • Patients with severe mental disorders such as psychosis, liver and kidney dysfunction, poor blood pressure or blood glucose control, severe depression and substance abuse, low IQ, and acute phase of severe stroke with definite limb dysfunction should also be excluded.

Sites / Locations

  • The 307th Hospital of Military Chinese People's Liberation ArmyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

Experimental

Experimental

Arm Label

Conservative treatment

Indirect vascular reconstruction surgery

direct vascular reconstruction surgery

Arm Description

Conservative treatment. The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, the prevention and treatment of secondary epilepsy, the control of intracranial hypertension(including the application of mannitol and glycerol fructose, etc.), and the corresponding symptomatic and neurotrophic treatment. Non-specific treatment is mainly deal with intracranial hematoma, including intraventricular drainage, intracranial hematoma evacuation, and ventriculoperitoneal shunt.

Indirect vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) is performed. The surgery is performed according to the procedures described by Matsushima.

Direct vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) bypass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And if necessary, the STA may not be preserved. The bone flap should be large enough to select the right recipient blood vessel.

Outcomes

Primary Outcome Measures

Rebleeding
All enrolled patients were followed up regularly by telephone, outpatient and inpatient visits. The observed end-point events of rebleeding

Secondary Outcome Measures

Severe Disability
Cerebral infarction resulting in severe disability (mRS score≥3)
Severe Disability or Death
Severe disability or death caused by other reasons
Vascular Reconstruction due to Progressive Ischemic Stroke or Progressive TIA
Patients in conservative treatment group needs vascular reconstruction due to progressive ischemic stroke or progressive TIA.

Full Information

First Posted
July 29, 2018
Last Updated
January 29, 2019
Sponsor
Affiliated Hospital to Academy of Military Medical Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT03627975
Brief Title
Effect of Surgical Revascularization on Hemorrhagic Moyamoya Disease
Acronym
ESRHMMD
Official Title
Effect of Surgical Revascularization and Conservative Treatment on Hemorrhagic Moyamoya Disease
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Unknown status
Study Start Date
October 1, 2017 (Actual)
Primary Completion Date
October 1, 2020 (Anticipated)
Study Completion Date
October 1, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Affiliated Hospital to Academy of Military Medical Sciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Moyamoya Disease(MMD), also known as spontaneous basilar artery occlusion, is characterized by the gradual thickening of arterial intima at the distal carotid artery and the proximal portion of anterior/middle cerebral artery, the gradual stenosis or occlusion of arterial lumen, and the compensatory expansion of basilar cerebral perforating arteries. Cerebral infarction and cerebral hemorrhage are common clinical symptoms of MMD with high morbidity of disability. For ischemic moyamoya disease, intracranial/extracranial revascularization is the preferred treatment. However, for patients with hemorrhagic moyamoya disease, there is controversy about whether to have surgical treatment, the timing and the method of surgical treatment, and the effect of surgical treatment to prevent rebleeding due to the lack of large sample, multi-center, prospective randomized studies. At present, the studies on the effect of revascularization and conservative treatment on hemorrhagic moyamoya disease are retrospective case analyses without randomized control. The sample size of these studies are small, and the conclusions obtained are inconsistent. Due to the differences in the epidemiology and episode type of moyamoya disease in different countries, there is no prospective, randomized controlled study of blood type moyamoya disease in China to confirm the efficacy of revascularization and lack of uniform norms and standards.
Detailed Description
Objective: The aim of this study is to perform a prospective, randomized study on hemorrhagic moyamoya disease to confirm the effect of revascularization in China, and to establish specifications and standards to guide the treatment options for hemorrhagic moyamoya disease as well. Design: This study is a single-center study and plan to include 108 patients. According to a random number table, hemorrhagic moyamoya patients will be assigned to three groups: conservative treatment group, direct revascularization group and indirect revascularization group. A prospective, randomized study will be carried out to evaluate the effect of revascularization and conservative treatment on the reduction of rebleeding risk and improvement of ischemia in adult patients with hemorrhagic moyamoya disease. Observation Measures: 1.Rebleeding; 2.Cerebral infarction resulting in severe disability (mRS score≥3); 3.Severe disability or death caused by other reasons; 4. Patients in conservative treatment group need revascularization due to progressive ischemic stroke or progressive Transient ischemic attack(TIA).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Moyamoya Disease
Keywords
revascularization, hemorrhagic moyamoya disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
108 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Conservative treatment
Arm Type
No Intervention
Arm Description
Conservative treatment. The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, the prevention and treatment of secondary epilepsy, the control of intracranial hypertension(including the application of mannitol and glycerol fructose, etc.), and the corresponding symptomatic and neurotrophic treatment. Non-specific treatment is mainly deal with intracranial hematoma, including intraventricular drainage, intracranial hematoma evacuation, and ventriculoperitoneal shunt.
Arm Title
Indirect vascular reconstruction surgery
Arm Type
Experimental
Arm Description
Indirect vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) is performed. The surgery is performed according to the procedures described by Matsushima.
Arm Title
direct vascular reconstruction surgery
Arm Type
Experimental
Arm Description
Direct vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) bypass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And if necessary, the STA may not be preserved. The bone flap should be large enough to select the right recipient blood vessel.
Intervention Type
Procedure
Intervention Name(s)
Conservative treatment
Other Intervention Name(s)
indirect revascularization, direct revascularization
Intervention Description
The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, prevention and treatment of secondary epilepsy, the control of intracranial hypertension, and the corresponding symptomatic and neurotrophic treatment. In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) will be performed according to the procedures described by Matsushima. In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) by pass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And the STA may not be preserved.
Primary Outcome Measure Information:
Title
Rebleeding
Description
All enrolled patients were followed up regularly by telephone, outpatient and inpatient visits. The observed end-point events of rebleeding
Time Frame
Through study completion, an average of 1 year
Secondary Outcome Measure Information:
Title
Severe Disability
Description
Cerebral infarction resulting in severe disability (mRS score≥3)
Time Frame
Through study completion, an average of 1 year
Title
Severe Disability or Death
Description
Severe disability or death caused by other reasons
Time Frame
Through study completion, an average of 1 year
Title
Vascular Reconstruction due to Progressive Ischemic Stroke or Progressive TIA
Description
Patients in conservative treatment group needs vascular reconstruction due to progressive ischemic stroke or progressive TIA.
Time Frame
Through study completion, an average of 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: DSA/MRA shows stenosis or occlusion in the distal internal carotid artery or the proximal portion of anterior/middle cerebral artery Abnormal vascular network appeared in the brain Lesions showed bilateral changes Age≥18 years With the onset of cerebral hemorrhage No cerebral infarction or cerebral hemorrhage occurred within the last month At least one month after the acute phase of cerebral hemorrhage or related diseases was treated Exclusion Criteria: Patients with moyamoya syndrome secondary to systemic diseases such as arteriosclerosis, sickle cell anemia, radiation therapy, etc.. Patients with severe mental disorders such as psychosis, liver and kidney dysfunction, poor blood pressure or blood glucose control, severe depression and substance abuse, low IQ, and acute phase of severe stroke with definite limb dysfunction should also be excluded.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lian Duan, Chief
Phone
0086-10-66947156
Email
keyan307@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lian Lian, Chief
Organizational Affiliation
The 307th Hospital of Military Chinese People's Liberation Army
Official's Role
Study Chair
Facility Information:
Facility Name
The 307th Hospital of Military Chinese People's Liberation Army
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100071
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lian Duan, Chief

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of Surgical Revascularization on Hemorrhagic Moyamoya Disease

We'll reach out to this number within 24 hrs